Cytokines secretion from human mesenchymal stem cells induced by bovine bone matrix
Source abstract
Abstract
BACKGROUND: Bovine bone matrix is a natural material that has been used in the treatment of bone lesions. In this study, bovine bone matrix Nukbone® (NKB) was investigated due its osteoconductive and osteoinductive properties. This biomaterial induces CBFA-1 activation and osteogenic differentiation, although the cytokines involved in these processes is still unknown. OBJECTIVE: The aim of this work was to determine the influence of NKB on the pro-osteoblastic and anti-osteoblastic cytokines secretion from human mesenchymal stem cells (hMSCs). METHODS: The hMSCs were cultured onto NKB and cytokines IL-2, IL-4, IL-6, IL-10, IL-12, IFN-γ and TNF-α were analized at 0-14 days by immunoassay. In addition, hemocompatibility of NKB and characterization of hMSCs were evaluated. RESULTS: NKB induces an increase on pro-osteoblastic cytokine secretion IL-4 and a decrease on anti-osteoblastic cytokine IL-6 secretion, at days 7 and 14 of cell culture. Interestingly, there was no statistical difference between secretion profiles of others cytokines analized. CONCLUSIONS: The up-regulation of IL-4 and down-regulation of IL-6, and the secretion profiles of other cytokines examined in this work, are findings that will contribute to the understanding of the role of NKB, and similar biomaterials, in bone homeostasis and in the osteoblastic differentiation of hMSCs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Mesenchymal stem cell research · Bone Tissue Engineering Materials · Bone Metabolism and Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
, , , , México
, , Universidad Autónoma de San Luis Potosí, , México
, , México
, , , México
References (45)
Show source-provided references
1. Extracellular matrix structure10.1016/j.addr.2015.11.001 ↗
2. Clinical and histological changes after ridge preservation with two xenografts: Preliminary results from a multicentre randomized controlled clinical trial10.1111/jcpe.12655 ↗
3. Histologic evaluation of osseous regeneration following combination therapy with platelet-rich plasma and Bio-Oss in a rat calvarial critical-size defect model10.1563/AAID-JOI-D-12-00075 ↗
4. Decellularized scaffolds as a platform for bioengineered organs10.1097/MOT.0000000000000051 ↗
5. 10.1177/204173141668030610.1177/2041731416680306 ↗
6. Cytotoxic and genotoxic effects of the exposition of human lymphocytes to a ceramic material in vitro
7. Caracterización de hueso de bovino anorgánico: Nukbone
8. Descripción histológica de la regeneración ósea en cresta iliaca de conejos implantados con Nukbone a las 4, 8, 12 y 16 semanas
9. Bone loss treatment, pseudoarthrosis, arthrodesis and benign tumors using xenoimplant: Clinical study
10. Nukbone promotes proliferation and osteoblastic differentiation of mesenchymal stem cells from human amniotic membrane
11. Isolation of human mesenchymal stem cells and their cultivation on the porous bone matrix10.3791/51999 ↗
12. Compressed collagen constructs with optimized mechanical properties and cell interactions for tissue engineering applications10.1016/j.ijbiomac.2017.11.117 ↗
13. Nano-structure designing promotion osseointegration of hydroxyapatite coated Ti-6Al-4V alloy implants in diabetic model10.1166/jbn.2019.2812 ↗
14. Influences of tantalum pentoxide and surface coarsening on surface roughness, hydrophilicity, surface energy, protein adsorption and cell responses to PEEK based biocomposite10.1016/j.colsurfb.2018.10.081 ↗
15. Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone defects10.1089/ten.tea.2011.0325 ↗
16. Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts
17. Human fetal mesenchymal stem cell secretome enhances bone consolidation in distraction osteogenesis
18. First-in-human study and clinical case reports of the alveolar bone regeneration with the secretome from human mesenchymal stem cells
19. Clinical study of bone regeneration by conditioned medium from mesenchymal stem cells after maxillary sinus floor elevation10.1097/ID.0000000000000618 ↗
20. The impact of mesenchymal stem cells and their secretome as a treatment for gliomas10.1016/j.biochi.2018.07.008 ↗
21. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: Involvement of IFN-gamma possibly induced from non-T cell population10.1016/S8756-3282(03)00213-8 ↗
22. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides10.1002/jcp.20563 ↗
23. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc expression and preventing its translocation to the nucleus10.1186/1471-2121-8-4 ↗
24. Human osteoclastogenic T cells and human osteoclastology
25. Immunology of gut bone signaling10.1007/978-3-319-66653-2_5 ↗
26. Interleukin-6 and osteoprotegerin systems in Paget’s disease of bone: Relationships to risedronate treatment10.1016/j.bone.2004.11.004 ↗
27. IL-1 plays an important role in the bone metabolism under physiological conditions10.1093/intimm/dxq431 ↗
28. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement10.1080/14653240500319234 ↗
29. Development of collagen-EDC scaffolds for skin tissue engineering: Physicochemical and biological characterization
30. International Organization for Standardization. ISO 10 993–4:2017 Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood, 3 ed. 2017, pp. 1–19.
31. IL-12p40 impairs mesenchymal stem cell-mediated bone regeneration via CD4+T cells10.1038/cdd.2016.72 ↗
32. Bone versus immune system10.1038/35046196 ↗
33. Osteoimmunology: Cytokines and the skeletal system
34. Interlekin-6 directly inhibits osteoclast differentiation by supressing receptor activator of NF-KappaB signaling pathways10.1074/jbc.M607999200 ↗
35. Interleukin-6 as a key player in systemic inflammation and joint destruction10.1016/j.autrev.2009.01.012 ↗
36. A controversial role for IL-12 in immune response and bone resorption at apical periodontal sites10.1155/2010/327417 ↗
37. Overview of interleukin-2 function, production and clinical applications10.1016/j.cyto.2004.06.010 ↗
38. IL-2 Family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation10.1016/j.coi.2011.08.003 ↗
39. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreases RANKL and RANK in a STAT6-dependent pathway10.1074/jbc.M510160200 ↗
40. Interlekin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts10.1111/j.1365-2567.2006.02538.x ↗
41. FTY-720P suppresses osteoclast formation by regulating expression of Interleukin-6 (IL-6), Interleukin-4 (IL-4), and Matrix Metalloproteinase 2 (MMP-2)10.12659/MSM.896690 ↗
42. Interleukin-6 induces the lineage commitment of bone marrow-derived mesenchymal multipotent cells through down-regulation of Sox2 by osteogenic transcription factors10.1096/fj.13-248567 ↗
43. The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells10.1111/j.1365-2141.1995.tb05605.x ↗
44. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma10.1007/s12026-014-8528-x ↗
45. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors10.1084/jem.182.5.1461 ↗